N/A
Completed N=64
Effect of Inflammation on Pharmacokinetics of Posaconazole
Mycoses
Source: ClinicalTrials.gov NCT02492802 ↗
Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L — 1.8; 23.5 mg/L — p=0.77
Summary
Posaconazole plasma concentration and inflammatory markers will be determined in all samples available from routine analysis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L |
1.8; 23.5 | 0.77 |
Eligibility Criteria
Inclusion Criteria
- >18 yrs
- receiving posaconazole
- Written informed consent
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT02492802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.